Teresa Blankmeyer Burke considers the problematic nature of gene therapy research aimed at eliminating hereditary deafness.
Françoise Baylis wonders how it is that in 14 months (from December 2015 to February 2017), the U.S. National Academy of Sciences and the U.S. National Academy of Medicine have moved human germline genome editing out of the category ‘irresponsible’ and into the category ‘permissible.’
Alice Dreger raises concerns about a pervasive pattern of non-evidence based assumptions driving practices in pediatric endocrinology.
Janet Farrell Leontiou reflects on her experience as an IVF patient who was misled into choosing several multiple embryo transfers.
Chelsea Cox questions the federal government’s recent decision to limit reimbursement for the cost of medical marijuana used by veterans to three grams a day.
Michael Orsini and Anne McGuire offer a critical disability studies perspective on the Hospital for Sick Children’s latest ad campaign.
Françoise Baylis discusses the response of the Canadian insurance industry to Bill S-201, An Act to prohibit and prevent genetic discrimination.